ACE and Hypertension: Thirty-seven patients (35.2%) presented arterial hypertension and 38 (36.2%) were receiving renin-angiotensin-aldosterone inhibitors, namely angiotensin-converting enzyme inhibitors (n=24, 22.9%), angiotensin receptor blockers (n=13, 12.4%), and spironolactone (n=1, 1.0%).